Biomedical Technology and Cell Therapy Research Laboratory, Department of Biomedical Engineering, Faculty of Medicine, McGill University, Montreal, QC, Canada.
Int J Nanomedicine. 2012;7:663-82. doi: 10.2147/IJN.S26882. Epub 2012 Feb 8.
The objective of this study was to develop angiopoietin-1 (Ang1)-expressing genetically modified human adipose tissue derived stem cells (hASCs) for myocardial therapy. For this, an efficient gene delivery system using recombinant baculovirus complexed with cell penetrating transactivating transcriptional activator TAT peptide/deoxyribonucleic acid nanoparticles (Bac-NP), through ionic interactions, was used. It was hypothesized that the hybrid Bac- NP(Ang1) system can efficiently transduce hASCs and induces favorable therapeutic effects when transplanted in vivo. To evaluate this hypothesis, a rat model with acute myocardial infarction and intramyocardially transplanted Ang1-expressing hASCs (hASC-Ang1), genetically modified by Bac-NP(Ang1), was used. Ang1 is a crucial pro-angiogenic factor for vascular maturation and neovasculogenesis. The released hAng1 from hASC-Ang1 demonstrated profound mitotic and anti-apoptotic activities on endothelial cells and cardiomyocytes. The transplanted hASC-Ang1 group showed higher cell retention compared to hASC and control groups. A significant increase in capillary density and reduction in infarct sizes were noted in the infarcted hearts with hASC-Ang1 treatment compared to infarcted hearts treated with hASC or the untreated group. Furthermore, the hASC-Ang1 group showed significantly higher cardiac performance in echocardiography (ejection fraction 46.28% ± 6.3%, P < 0.001 versus control, n = 8) than the hASC group (36.35% ± 5.7%, P < 0.01, n = 8), 28 days post-infarction. The study identified Bac-NP complex as an advanced gene delivery vehicle for stem cells and demonstrated its potential to treat ischemic heart disease with high therapeutic index for combined stem cell-gene therapy strategy.
本研究旨在开发表达血管生成素-1(Ang1)的基因修饰人脂肪组织来源的干细胞(hASCs)用于心肌治疗。为此,使用了一种通过离子相互作用将重组杆状病毒复合物与穿透细胞的转录激活转录激活剂 TAT 肽/脱氧核糖核酸纳米颗粒(Bac-NP)结合的高效基因传递系统。假设杂交 Bac-NP(Ang1)系统可以有效地转导 hASCs,并在体内移植时诱导有利的治疗效果。为了评估这一假设,使用了急性心肌梗死大鼠模型和通过 Bac-NP(Ang1)基因修饰的心肌内移植表达 Ang1 的 hASCs(hASC-Ang1)。Ang1 是血管成熟和新生血管形成的关键促血管生成因子。从 hASC-Ang1 释放的 hAng1 对内皮细胞和心肌细胞表现出明显的有丝分裂和抗凋亡活性。与 hASC 和对照组相比,移植的 hASC-Ang1 组显示出更高的细胞保留率。与 hASC 或未处理组相比,用 hASC-Ang1 处理的梗死心脏的毛细血管密度显著增加,梗死面积减小。此外,与 hASC 组(28 天后为 36.35%±5.7%,n=8,P<0.01)相比,hASC-Ang1 组的超声心动图(射血分数 46.28%±6.3%,P<0.001,n=8)的心脏功能明显更高。该研究确定 Bac-NP 复合物是一种先进的干细胞基因传递载体,并证明其具有通过联合干细胞-基因治疗策略治疗缺血性心脏病的潜力,具有高治疗指数。